Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

Fig. 3

EORTC-QLQ-C30 – Global Health Status. Depicted are box-and-whisker plots showing the scores of global health status in the ITT population across Arm A (Cap+Bev/Eve+Exe) and Arm B (Eve+Exe/Cap+Bev) at baseline and at week 12 in each treatment phase. The scale ranges from 0 to a maximum of 100. The horizontal solid line within each box shows the median. The line graphs display the mean Quality of Life over time per study arm. The lines extending vertically from the boxes (whiskers) indicate the variability outside the upper and lower quartiles. The whiskers span 1.5 x IQR (interquartile range, i.e. the difference between the quartiles). The individual small circles represent the outliers. EORTC QLQ-C30 = European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (30-item core module); n = number; QL2 = Quality of life

Back to article page